Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
about
The role of morphine glucuronides in cancer pain.Opioid rotation for cancer pain: rationale and clinical aspects.Contemporary drug therapy in palliative care: new directions.Oral-parenteral conversion factor for morphine in palliative cancer care: a prospective randomized crossover pilot studyDifferential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administration? Six case histories.Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability.Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.Dual modulation of the T-cell receptor-activated signal transduction pathway by morphine in human T lymphocytes.Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.Glucuronidation: driving factors and their impact on glucuronide disposition
P2860
Q33727191-284C478C-F9B9-4097-8D68-399CEE03DE35Q33765787-15C9EDBB-B9FC-4FB6-BBAC-67012A91BED3Q34280867-7FE97841-764C-4AF2-B139-2D573A45106CQ35391296-4AFB306E-DF45-4BE0-BF12-8539B1BB691CQ35827481-8E22EB48-0BF9-49A8-8856-2C411EDF1B4BQ37142434-2925249E-C01B-4906-A0C4-37AB6F1A8D06Q39395812-C7925038-CE9D-43E8-A219-193630A16532Q42538403-B1D45E02-DF19-41A8-93BE-FC46D7A90729Q43260922-3D1024FF-24AE-495C-8ABB-8ADBBE62B19CQ43968416-EF613241-4543-498A-B92F-F706F1477347Q44476215-07C063B6-BD89-46C3-94EC-8BD70B0E0911Q44862502-2108E4CE-3667-4C82-BB8C-FC6414E1997CQ47930548-7CBC3F7F-F8DA-4DC8-98B0-6A1FEBF7DA76Q48135046-D87DDC96-BCAD-49EE-A46E-7C737001302EQ48721652-74749FAA-072C-41A2-9A3E-1098E5D2F34EQ56030213-E97F98DC-870D-4C30-BE0A-6B009BAC3A5F
P2860
Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Morphine and morphine metaboli ...... oral morphine administration.
@en
Morphine and morphine metaboli ...... oral morphine administration.
@nl
type
label
Morphine and morphine metaboli ...... oral morphine administration.
@en
Morphine and morphine metaboli ...... oral morphine administration.
@nl
prefLabel
Morphine and morphine metaboli ...... oral morphine administration.
@en
Morphine and morphine metaboli ...... oral morphine administration.
@nl
P2093
P1433
P1476
Morphine and morphine metaboli ...... oral morphine administration.
@en
P2093
P304
P356
10.1016/0304-3959(94)00268-J
P407
P577
1995-08-01T00:00:00Z